VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

Vascular Biogenics Ltd. (NASDAQ:VBLT) began the Phase III OVAL trial of ofranergene obadenovec (VB-111) to treat recurrent platinum-resistant ovarian cancer.

The U.S.

Read the full 220 word article

User Sign In